RESUMEN
IMPORTANCE: Intracranial stenosis is one of the most common etiologies of stroke. To our knowledge, no randomized clinical trials have compared balloon-expandable stent treatment with medical therapy in symptomatic intracranial arterial stenosis. OBJECTIVE: To evaluate the efficacy and safety of the balloon-expandable stent plus medical therapy vs medical therapy alone in patients with symptomatic intracranial stenosis (≥70%). DESIGN, SETTING, AND PATIENTS: VISSIT (the Vitesse Intracranial Stent Study for Ischemic Stroke Therapy) trial is an international, multicenter, 1:1 randomized, parallel group trial that enrolled patients from 27 sites (January 2009-June 2012) with last follow-up in May 2013. INTERVENTIONS: Patients (N = 112) were randomized to receive balloon-expandable stent plus medical therapy (stent group; n = 59) or medical therapy alone (medical group; n = 53). PRIMARY OUTCOME MEASURE: a composite of stroke in the same territory within 12 months of randomization or hard transient ischemic attack (TIA) in the same territory day 2 through month 12 postrandomization. A hard TIA was defined as a transient episode of neurological dysfunction caused by focal brain or retinal ischemia lasting at least 10 minutes but resolving within 24 hours. Primary safety measure: a composite of any stroke, death, or intracranial hemorrhage within 30 days of randomization and any hard TIA between days 2 and 30 of randomization. Disability was measured with the modified Rankin Scale and general health status with the EuroQol-5D, both through month 12. RESULTS: Enrollment was halted by the sponsor after negative results from another trial prompted an early analysis of outcomes, which suggested futility after 112 patients of a planned sample size of 250 were enrolled. The 30-day primary safety end point occurred in more patients in the stent group (14/58; 24.1% [95% CI, 13.9%-37.2%]) vs the medical group (5/53; 9.4% [95% CI, 3.1%-20.7%]) (P = .05). Intracranial hemorrhage within 30 days occurred in more patients in the stent group (5/58; 8.6% [95% CI, 2.9%-19.0%]) vs none in the medical group (95% CI, 0%-5.5%) (P = .06). The 1-year primary outcome of stroke or hard TIA occurred in more patients in the stent group (21/58; 36.2% [95% CI, 24.0-49.9]) vs the medical group (8/53; 15.1% [95% CI, 6.7-27.6]) (P = .02). Worsening of baseline disability score (modified Rankin Scale) occurred in more patients in the stent group (14/58; 24.1% [95% CI, 13.9%-37.2%]) vs the medical group (6/53; 11.3% [95% CI, 4.3%-23.0%]) (P = .09).The EuroQol-5D showed no difference in any of the 5 dimensions between groups at 12-month follow-up. CONCLUSIONS AND RELEVANCE: Among patients with symptomatic intracranial arterial stenosis, the use of a balloon-expandable stent compared with medical therapy resulted in an increased 12-month risk of added stroke or TIA in the same territory, and increased 30-day risk of any stroke or TIA. These findings do not support the use of a balloon-expandable stent for patients with symptomatic intracranial arterial stenosis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00816166.
Asunto(s)
Estenosis Carotídea/terapia , Stents/efectos adversos , Accidente Cerebrovascular/prevención & control , Insuficiencia Vertebrobasilar/terapia , Adulto , Anciano , Estenosis Carotídea/complicaciones , Femenino , Humanos , Hemorragias Intracraneales/etiología , Masculino , Persona de Mediana Edad , Riesgo , Accidente Cerebrovascular/etiología , Resultado del Tratamiento , Insuficiencia Vertebrobasilar/complicacionesRESUMEN
BACKGROUND: Cerebrospinal fluid (CSF) shunt infection is a major cause of morbidity and mortality in the treatment of hydrocephalus and is associated with significant medical cost. Several studies have demonstrated the efficacy of antibiotic-impregnated (AI) shunt catheters in reducing CSF shunt infection; however, providers remain reluctant to adopt AI catheters into practice because of the increased upfront cost. The objective of this study was to determine if the use of AI catheters provided cost savings in a large nationwide database. METHODS: Hospital discharge and billing records from the Premier Perspective Database from 2003-2009 were retrospectively reviewed to identify all adult and pediatric patients undergoing de novo ventricular shunt placement. The incidence of shunt infection within 1 year of implantation was determined. Shunt infection-related cost was defined as all inpatient billing costs incurred during hospitalization for treatment of shunt infection. RESULTS: In 287 U.S. hospitals, 10,819 adult (AI catheters, 963; standard catheters, 9856) and 1770 pediatric (AI catheters, 229; standard catheters, 1541) patients underwent ventricular shunt placement. AI catheters were associated with significant reduction in infection for both adult (2.2% vs. 3.6%, P = 0.02) and pediatric (2.6% vs. 7.1%, P < 0.01) patients. Total infection-related costs were $17,371,320 ($45,714 ± $49,745 per shunt infection) for adult patients and $6,508,064 ($56,104 ± $65,746 per shunt infection) for pediatric patients. Infection-related cost per 100 de novo shunts placed was $120,534 for AI catheters and $162,659 for standard catheters in adult patients and $165,087 for AI catheters and $395,477 for standard catheters in pediatric patients. CONCLUSIONS: In analysis of this large, nationwide database, AI catheters were found to be associated with a significant reduction in infection incidence, resulting in tremendous cost savings. AI catheters were associated with a cost savings of $42,125 and $230,390 per 100 de novo shunts placed in adult and pediatric patients, respectively.
Asunto(s)
Antibacterianos/economía , Antibacterianos/uso terapéutico , Infecciones Relacionadas con Catéteres/economía , Infecciones Relacionadas con Catéteres/prevención & control , Derivaciones del Líquido Cefalorraquídeo/economía , Hidrocefalia/economía , Hidrocefalia/cirugía , Adolescente , Adulto , Anciano , Antibacterianos/administración & dosificación , Catéteres , Niño , Preescolar , Ahorro de Costo , Bases de Datos Factuales , Femenino , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
OBJECT: The real-world effectiveness of antibiotic-impregnated shunt catheters to reduce the incidence of shunt infections is still debated. The literature to date consists mostly of small, single-institution studies. The aim of this study was to assess the incidence of infection for antibiotic-impregnated catheters (AICs) versus standard shunt catheters in a large nationwide administrative database. METHODS: The authors retrospectively reviewed hospital discharge and billing records from the Premier Perspective Database from April 2003 to July 2009 to identify all adult and pediatric patients undergoing de novo ventricular shunt placement. The primary end point was the incidence of shunt infection within 1 year of implantation. Multivariate logistical regression was performed to determine factors associated with increased incidence of infection. RESULTS: A total of 10,819 adult (AIC, 963; standard catheter, 9856) and 1770 pediatric (AIC, 229; standard catheter, 1541) patients underwent ventricular shunt placement in 287 US hospitals. Overall, the incidence of infection was 3.5% in adults (n=380) and 6.6% in pediatric patients (n=116). AICs were associated with significant reduction in infection for both adult (2.2% vs 3.6%, p=0.02) and pediatric (2.6% vs 7.1%, p<0.01) patients. AIC use was associated with reduced infection regardless of hospital size, annual shunt volume, hospital location, or patient risk factors and remained associated with a reduced infection in multivariate analysis for both adult (p=0.02) and pediatric (p=0.02) patients. CONCLUSIONS: The use of antibiotic-impregnated shunt catheters was associated with a reduction in shunt infections for both adult and pediatric patients. This provides further support that AICs may represent a reliable means of reducing shunt infections for both adult and pediatric patients.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Infecciones Bacterianas/prevención & control , Catéteres/microbiología , Derivaciones del Líquido Cefalorraquídeo/efectos adversos , Hidrocefalia/terapia , Adolescente , Anciano , Anciano de 80 o más Años , Infecciones Bacterianas/epidemiología , Derivaciones del Líquido Cefalorraquídeo/instrumentación , Niño , Preescolar , Femenino , Humanos , Incidencia , Modelos Logísticos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
OBJECTIVE: To evaluate the role of copy number abnormalities detectable using chromosomal microarray (CMA) testing in patients with epilepsy at a tertiary care center. METHODS: We identified patients with International Classification of Diseases, ninth revision (ICD-9) codes for epilepsy or seizures and clinical CMA testing performed between October 2006 and February 2011 at Boston Children's Hospital. We reviewed medical records and included patients who met criteria for epilepsy. We phenotypically characterized patients with epilepsy-associated abnormalities on CMA. RESULTS: Of 973 patients who had CMA and ICD-9 codes for epilepsy or seizures, 805 patients satisfied criteria for epilepsy. We observed 437 copy number variants (CNVs) in 323 patients (1-4 per patient), including 185 (42%) deletions and 252 (58%) duplications. Forty (9%) were confirmed de novo, 186 (43%) were inherited, and parental data were unavailable for 211 (48%). Excluding full chromosome trisomies, CNV size ranged from 18kb to 142Mb, and 34% were >500kb. In at least 40 cases (5%), the epilepsy phenotype was explained by a CNV, including 29 patients with epilepsy-associated syndromes and 11 with likely disease-associated CNVs involving epilepsy genes or "hotspots." We observed numerous recurrent CNVs including 10 involving loss or gain of Xp22.31, a region described in patients with and without epilepsy. INTERPRETATION: Copy number abnormalities play an important role in patients with epilepsy. Because the diagnostic yield of CMA for epilepsy patients is similar to the yield in autism spectrum disorders and in prenatal diagnosis, for which published guidelines recommend testing with CMA, we recommend the implementation of CMA in the evaluation of unexplained epilepsy.
Asunto(s)
Trastornos de los Cromosomas/complicaciones , Variaciones en el Número de Copia de ADN/genética , Epilepsia/etiología , Epilepsia/genética , Electroencefalografía , Femenino , Perfilación de la Expresión Génica , Humanos , Clasificación Internacional de Enfermedades , Masculino , Análisis de Secuencia por Matrices de Oligonucleótidos , Estudios RetrospectivosRESUMEN
BACKGROUND AND PURPOSE: The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of stroke therapies. At STAIR VIII, consensus recommendations were developed for clinical trial strategies to demonstrate the benefit of endovascular reperfusion therapies for acute ischemic stroke. SUMMARY OF REVIEW: Prospects for success with forthcoming endovascular trials are robust, because new neurothrombectomy devices have superior reperfusion efficacy compared with earlier-generation interventions. Specific recommendations are provided for trial designs in 3 populations: (1) patients undergoing intravenous fibrinolysis, (2) early patients ineligible for or having failed intravenous fibrinolysis, and (3) wake-up and other late-presenting patients. Among intravenous fibrinolysis-eligible patients, key principles are that CT or MRI confirmation of target arterial occlusions should precede randomization; endovascular intervention should be pursued with the greatest rapidity possible; and combined intravenous and neurothrombectomy therapy is more promising than neurothrombectomy alone. Among patients ineligible for or having failed intravenous fibrinolysis, scientific equipoise was affirmed and the need to randomize all eligible patients emphasized. Vessel imaging to confirm occlusion is mandatory, and infarct core and penumbral imaging is desirable in later time windows. Additional STAIR VIII recommendations include approaches to test multiple devices in a single trial, utility weighting of disability end points, and adaptive designs to delineate time and tissue injury thresholds at which benefits from intervention no longer accrue. CONCLUSIONS: Endovascular research priorities in acute ischemic stroke are to perform trials testing new, highly effective neuro thrombectomy devices rapidly deployed in patients confirmed to have target vessel occlusions.
Asunto(s)
Isquemia Encefálica/cirugía , Ensayos Clínicos como Asunto , Proyectos de Investigación , Accidente Cerebrovascular/cirugía , Trombectomía/instrumentación , Isquemia Encefálica/tratamiento farmacológico , Fibrinolíticos/uso terapéutico , Humanos , Accidente Cerebrovascular/tratamiento farmacológico , Terapia Trombolítica/métodosRESUMEN
BACKGROUND: External ventricular drainage (EVD) catheters provide reliable and accurate means of monitoring intracranial pressure and alleviating elevated pressures via drainage of cerebrospinal fluid (CSF). CSF infections occur in approximately 9% of patients. Antibiotic-impregnated (AI) EVD catheters were developed with the goal of reducing the occurrence of EVD catheter-related CSF infections and their associated complications. OBJECTIVE: To present an international, prospective, randomized, open-label trial to evaluate infection incidence of AI vs standard EVD catheters. METHODS: Infection was defined as (1) proven infection, positive CSF culture and positive Gram stain or (2) suspected infection: (A) positive CSF culture with no organisms identified on initial Gram stain; (B) negative CSF culture with a gram-positive or -negative stain; (C) CSF leukocytosis with a white blood cell/red blood cell count >0.02. RESULTS: Four hundred thirty-four patients underwent implantation of an EVD catheter. One hundred seventy-six patients in the AI-EVD cohort and 181 in the standard EVD catheter cohort were eligible for evaluation of infection. The 2 groups were similar in all clinical characteristics. Proven infection was documented in 9 (2.5%) patients (AI: 4 [2.3%] vs standard: 5 [2.8%], P = 1.0). Suspected infection was documented in 31 (17.6%) patients receiving AI and 37 (20.4%) patients receiving standard EVD catheters, P = .504. Duration of time to suspected infection was prolonged in the AI cohort (8.8 ± 6.1 days) compared with the standard EVD cohort (4.6 ± 4.2 days), P = .002. CONCLUSION: AI-EVD catheters were associated with an extremely low rate of catheter-related infections. AI catheters were not associated with risk reduction in EVD infection compared to standard catheters. Use of AI-EVD catheters is a safe option for a wide variety of patients requiring CSF drainage and monitoring, but the efficacy of AI-EVD catheters was not supported in this trial.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/etiología , Infecciones Relacionadas con Catéteres/etiología , Derivaciones del Líquido Cefalorraquídeo/efectos adversos , Adulto , Anciano , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Relacionadas con Catéteres/tratamiento farmacológico , Estudios de Cohortes , Femenino , Humanos , Cooperación Internacional , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Factores de Tiempo , Adulto JovenRESUMEN
OBJECT: Cerebrospinal fluid shunt infections are associated with significant morbidity and mortality in the treatment of adult and pediatric hydrocephalus. Antibiotic-impregnated shunt (AIS) catheters have been used with the aim of reducing shunt infection. While many studies have demonstrated a reduction in shunt infection with AIS, this reported efficacy has varied within the literature. METHODS: The authors performed a systematic literature review to identify all published articles comparing the incidence of CSF shunt infection in AIS versus non-AIS catheters. The incidence of infection for AIS versus non-AIS catheters was calculated using the Mantel-Haenszel common odds ratio, and baseline demographics were compared between AIS and non-AIS cohorts. RESULTS: Twelve AIS versus non-AIS cohort comparisons were identified in the literature (5 pediatric hydrocephalus, 3 adult hydrocephalus, and 4 mixed populations). In a total of 5613 reported shunt procedures (2664 AISs vs 2949 non-AISs), AISs were associated with a reduction in shunt infection (3.3% vs 7.2%; OR 0.439, p < 0.0001). In 787 shunt procedures for adult hydrocephalus (427 AIS vs 360 non-AIS), AISs were associated with reduction in shunt infection (0.9% vs 5.8%; OR 0.153, p < 0.0001). In 1649 shunt procedures for pediatric hydrocephalus (854 AIS vs 795 non-AIS), AISs were associated with reduction in shunt infection (5.0% vs 11.2%; OR 0.421, p < 0.0001). CONCLUSIONS: The authors' systematic review of the literature demonstrates that AIS catheters are associated with a significant reduction over non-AIS catheters in the reported incidence of CSF shunt infection in adult and pediatric populations. The AIS catheters do not appear to be associated with an increased incidence of antibiotic-resistant microorganisms. Prospective, randomized trials are needed to firmly assess and confirm this apparent difference in infection incidence.
Asunto(s)
Antibacterianos/uso terapéutico , Derivaciones del Líquido Cefalorraquídeo , Hidrocefalia/epidemiología , Hidrocefalia/cirugía , Infecciones Relacionadas con Prótesis/epidemiología , Infecciones Relacionadas con Prótesis/prevención & control , Derivaciones del Líquido Cefalorraquídeo/efectos adversos , Derivaciones del Líquido Cefalorraquídeo/métodos , Derivaciones del Líquido Cefalorraquídeo/estadística & datos numéricos , Niño , Humanos , IncidenciaRESUMEN
Nerve conduction studies (NCS) and needle electromyography are useful and established diagnostic procedures for evaluating patients with signs and symptoms of neuromuscular disease. Although technological advances have occurred since the introduction of commercial electromyography instrumentation in the 1950s, most improvements have been evolutionary and were designed to benefit traditional users--neurologists and physiatrists specializing in electromyography. In the past seven years, instruments have been introduced that automate NCS and thereby enable a broader group of physicians, including internists and orthopedic surgeons, to perform these studies and utilize electromyographic data in the care of their patients. Automated NCS devices are an example of what Clayton Christensen terms a "disruptive innovation." In this article, automated NCS is contrasted with traditional electromyography, and the challenges and opposition to its widespread adoption are explored.
Asunto(s)
Electromiografía/métodos , Conducción Nerviosa/fisiología , Sistemas de Atención de Punto/organización & administración , Automatización , Electrodiagnóstico/tendencias , Electromiografía/tendencias , Humanos , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/fisiopatología , Sociedades Médicas/organización & administraciónRESUMEN
INTRODUCTION: Nerve conduction studies (NCS) are increasingly being performed at the point-of-service by family medicine, primary care, and internal medicine (FM/PCP/IM) physicians. Carpal tunnel syndrome (CTS) is a common neuropathy often diagnosed with the aid of NCS. METHODS: A retrospective analysis of a point-of-service NCS data registry was conducted; 1190 patients who underwent NCS by 613 FM/PCP/IM physician practices, for evaluation of CTS were analyzed. Utility measures included demographic and electrophysiological characteristics of study population, adherence to evidence-based testing guidelines, and relevance of diagnostic outcomes. RESULTS: Tested patients tended to be over 40, female, and overweight or obese. The median nerve distal motor latency was 4.4 +/- 1.2 ms; 92.6% of studies met the testing guideline; 30.5% of tested limbs yielded normal results; 53.1% CTS; 5.4% ulnar neuropathy; and 11.0% nonspecific upper extremity neuropathy. DISCUSSION: This study demonstrated that point-of-service NCS by FM/PCP/IM physicians for CTS was applied to appropriate patient subpopulations, was performed in accordance with evidence-based testing parameters, and generated relevant diagnostic outcomes.
Asunto(s)
Síndrome del Túnel Carpiano/diagnóstico , Medicina Familiar y Comunitaria , Conducción Nerviosa , Atención Primaria de Salud , Adulto , Anciano , Medicina Basada en la Evidencia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Nervio CubitalRESUMEN
BACKGROUND: Nerve conduction studies (NCS) are the most objective measure of nerve function, and their use is recommended in the clinical and epidemiological evaluation of diabetic polyneuropathy (DPN). The purpose of this study was to utilize automated NCS technology to characterize nerve conduction of patients with diabetes in primary care settings. METHODS: The Diabetes cohort was drawn from 28 community clinics. The Control cohort consisted of subjects without diabetes and without evidence of neuropathy. Bilateral peroneal NCS were performed with an automated NCS instrument (NC-stat, NeuroMetrix, Inc., Waltham, MA). Neuropathic symptoms were quantified using an abbreviated form of the NTSS-6 questionnaire. Risk factors for abnormal NCS were determined using multivariate regression modeling. RESULTS: Data were collected for 172 control subjects and 1,358 subjects with diabetes. Statistically significant differences in peroneal NCS were found. Of the Diabetes cohort, 75.1% had at least one NCS abnormality, and 53.2% had bilateral abnormalities. Of the asymptomatic patients, 45% had bilateral NCS abnormalities. By contrast, 40% of those with clinically significant symptoms lacked bilateral NCS abnormalities. Independent predictors for bilateral NCS abnormalities were age, height, weight, hemoglobin A1c (HbA1c), and duration of diabetes. Up to 16% of the variance in NCS measurements was explained by HbA1c, duration of diabetes, and several demographic variables. CONCLUSIONS: This study suggests that automated NCS can provide nerve conduction confirmation of DPN in primary care settings and has clinical utility. These findings have important implications for the clinical and epidemiological evaluation of DPN.
Asunto(s)
Neuropatías Diabéticas/diagnóstico , Conducción Nerviosa , Atención Primaria de Salud , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Conducción Nerviosa/fisiología , Examen Neurológico/instrumentación , Nervio Peroneo/fisiología , Factores de RiesgoRESUMEN
OBJECTIVE: To quantify nerve conduction study (NCS) reproducibility utilizing an automated NCS system (NC-stat, NeuroMetrix, Inc.). METHOD: Healthy volunteers without neuropathic symptoms participated in the study. Their median, ulnar, peroneal, and tibial nerves were tested twice (7 days apart) by the same technician with an NC-stat instrument. Pre-fabricated electrode arrays specific to each nerve were used. Both motor responses (compound motor action potential [CMAP] and F-waves - all nerves) and sensory responses (sensory nerve action potentials [SNAP] - median and ulnar nerves only) were recorded following supramaximal stimuli. Automated algorithms determined all NCS parameters: distal motor latency (DML), mean F-wave latency (FWL), distal sensory latency (DSL), CMAP amplitude, and SNAP amplitude. Latency was adjusted for skin temperature deviation from reference. Pearson correlation coefficient (CC), intraclass correlation coefficient (ICC), coefficient of variance (CoV), and relative intertrial variation (RIV) were calculated. RESULTS: Fifteen subjects participated in either upper or lower extremity studies with nine participating in both. With the exception of CMAP amplitude, all parameters had CoV less than 0.06. Upper extremity amplitude parameters had CCs greater than 0.85. CCs for latencies were greater than 0.80 except for the median nerve FWL (CC = 0.69). For lower extremity nerves, ICCs were highest for mean FWL (>0.90), followed by DML (>0.82) and then CMAP (peroneal 0.33, tibial 0.73). The 10th to 90th RIV percentiles were bounded by +/-7% for F-wave latencies; +/- 9% for all DSLs; and +/- 11% for DML (except peroneal at 15%). CONCLUSIONS: The reproducibility of NCS parameters obtained with an automated NCS instrument compared favorably with traditional electromyography laboratories. F-wave latencies had the highest repeatability, followed by DML, DSL, SNAP and CMAP amplitude. Given their high reproducibility, automated NCS instrument may encourage wider utilization of NCS in clinical and research applications.
Asunto(s)
Conducción Nerviosa , Potenciales de Acción , Adulto , Algoritmos , Brazo , Automatización , Electromiografía/instrumentación , Electromiografía/estadística & datos numéricos , Electrofisiología/instrumentación , Electrofisiología/estadística & datos numéricos , Femenino , Humanos , Pierna , Masculino , Persona de Mediana Edad , Neuronas Motoras/fisiología , Neuronas Aferentes/fisiología , Reproducibilidad de los ResultadosAsunto(s)
Síndrome del Túnel Carpiano/diagnóstico , Electrodiagnóstico/métodos , Enfermedades Profesionales/diagnóstico , Síndrome del Túnel Carpiano/fisiopatología , Interpretación Estadística de Datos , Técnicas de Diagnóstico Neurológico , Humanos , Nervio Mediano/fisiopatología , Conducción Nerviosa/fisiología , Sensibilidad y EspecificidadRESUMEN
PURPOSE: To identify predictors of outcome and of electrophysiologic recovery in patients with carpal tunnel syndrome (CTS) treated by endoscopic carpal tunnel release using a nerve conduction testing system (NC-Stat; NEUROMetrix, Inc, Waltham, MA). METHODS: Validity of the automated nerve conduction testing system was shown by comparing presurgical distal motor latencies (DMLs) against a reference obtained by referral to an electromyography laboratory. The DML was evaluated in 48 patients with CTS. Measurements were obtained within 1 hour of surgery and at 2 weeks, 6 weeks, 3 months, and 6 months after carpal tunnel release. Presurgical and postsurgical DMLs were then compared and correlated with variables and possible predictors of outcome including age, body mass index, gender, and presurgical DMLs. RESULTS: The automated nerve conduction testing system DMLs matched those of reference electromyography/nerve conduction study values with high correlation. Sensitivity of the automated nerve conduction testing system when compared with a standardized CTS case definition was 89%, with a specificity of 95%. A significant correlation was found between the DML before release and the DML 1 hour after release. Moreover, maximal postsurgical DML improvement was highly dependent on the presurgical DML, with no improvement shown for the <4-ms group, mild improvement for the 4-to-6-ms group, and maximal improvement in the >6-ms group. Among the clinical variables of age, gender, and body mass index only age was mildly predictive of postrelease DML changes at 6 months. No other correlations between clinical variables and postsurgical DMLs were significant. In addition the predictive value of age was lost when combined with the presurgical DML in a multivariate analysis. CONCLUSIONS: Postsurgical changes in the median nerve DML were highly dependent on the prerelease latency. The sensitivity and specificity of a nerve conduction monitoring system in detecting and aiding in the diagnosis of CTS is useful in the long-term management of patients with CTS and can aid in determining the level of improvement in median nerve function after endoscopic carpal tunnel release.
Asunto(s)
Síndrome del Túnel Carpiano/cirugía , Nervio Mediano/cirugía , Conducción Nerviosa/fisiología , Recuperación de la Función/fisiología , Adulto , Anciano , Síndrome del Túnel Carpiano/fisiopatología , Electrofisiología , Endoscopía , Femenino , Humanos , Masculino , Nervio Mediano/fisiopatología , Persona de Mediana Edad , Neuronas Motoras/fisiología , Análisis Multivariante , Evaluación de Resultado en la Atención de Salud , Periodo Posoperatorio , Valor Predictivo de las Pruebas , Cuidados Preoperatorios , Estudios Prospectivos , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
BACKGROUND: Diabetic peripheral neuropathy (DPN) is a common, disabling, and costly complication of diabetes mellitus. Although there are multiple methods for detecting and monitoring DPN, nerve conduction studies (NCS) are generally considered to be the most sensitive and reproducible. However, utilization of NCS in patients with diabetes is low, presumably because of limited access and economic issues. Advanced point-of-service NCS systems, already widely used in the assessment of entrapment neuropathies, may address these issues in the arena of diabetes. METHODS: Seventeen patients with diabetes and clinical evidence of neuropathy were enrolled in the study. NCS were performed using the NC-stat nerve conduction testing system (NEUROMetrix, Inc., Waltham, MA) and compared against results from a neurologist-supervised study using a standard electromyography system, which was considered the reference method. Results for ulnar and median distal motor latencies (DMLs) and F-waves, obtained by both methods, were compared with each other. The NC-stat measurements were also compared with a historical control population. RESULTS: A high correlation between the two methods of NCS assessment was demonstrated. The Pearson correlation coefficients between the NC-stat system and the reference measurements were 0.96 (DML) and 0.89 (F-wave latency) for the median nerve and 0.70 (DML) and 0.78 (F-wave latency) for the ulnar nerve. Significant differences were observed between the NC-stat and reference median (P < 0.001, paired t test) and ulnar (P < 0.05, paired t test) nerve DMLs. F-wave latencies did not demonstrate significant differences (P > 0.05, paired t test). The rate of abnormalities ranged from 17.7% for the median nerve DML to 26.7% for the ulnar nerve F-wave latency. The rate of upper extremity nerve involvement in DPN according to a case definition requiring both median and ulnar nerve abnormalities was 25.0%. The rate of median neuropathy at the wrist, which is the second most common neuropathy in individuals with diabetes, was 17.6%. CONCLUSIONS: NC-stat-based NCS of the median and ulnar nerves provide results similar to those obtained with traditional neurologist-supervised NCS using a standard electromyography system. The number of subjects meeting electrophysiological criteria for DPN, affecting the upper extremities, is similar to prior studies. The widespread availability of the NC-stat system may provide a robust and objective method for identifying DPN and other neuropathies in patients with diabetes.
Asunto(s)
Neuropatías Diabéticas/fisiopatología , Electrofisiología/instrumentación , Electrofisiología/métodos , Nervio Mediano/fisiopatología , Nervio Cubital/fisiopatología , Técnicas Biosensibles , Humanos , Conducción Nerviosa , Nervio Peroneo/fisiopatologíaRESUMEN
Homocystinuria usually presents with ectopia lentis, mental retardation, thromboembolic complications, and skeletal abnormalities. Whereas neuropsychiatric abnormalities are often recognized in untreated homocystinuria, initial presentation with acute psychosis has only rarely been reported. We describe a previously well 17-year-old adolescent with an acute psychosis characterized by auditory and visual hallucinations and marked paranoia who was found to have pyridoxine-responsive homocystinuria. His mental state normalized within several weeks of inception of pyridoxine and antipsychotic therapy. Pyridoxine-responsive homocystinuria is commonly missed on neonatal screens and should be recognized as a potentially treatable cause of acute psychosis in childhood and adolescence.